NextFin News - Gujarat Themis Biosyn has completed its ¥21.5 billion acquisition of Japan's MicroBiopharm using a financing package led by a private-credit fund rather than a traditional bank syndicate - a deal that signals how mid-sized Indian manufacturers are turning to alternative lenders to fund cross-border expansion.
Gujarat Themis Biosyn Limited (GTBL) said on September 18 that it closed the purchase of 100% of MicroBiopharm Japan Co., Ltd. (MBJ) through its wholly owned Japanese subsidiary, Themis Biosyn Japan Limited, after receiving customary regulatory approvals. The consideration of ¥21.5 billion (about ₹1,300 crore, or roughly $145 million) was funded through what the company called an optimal mix of debt and equity.
Behind that plain wording sits the real story. GTBL put ₹475 crore of equity and ₹745 crore of debt into its Japanese acquisition vehicle, Themis Biosyn Japan, and arranged a further loan facility of up to ₹800 crore. Avendus Capital structured the full acquisition financing across onshore and offshore debt, with Avendus Structured Credit Fund III acting as the lead investor in the onshore portion. Deloitte India advised GTBL on the transaction; Tokyo International Law Office served as legal counsel.
The deal was first announced on May 22, 2026, when GTBL signed a definitive agreement to buy MBJ from funds managed or advised by T Capital Partners, a Japan-based private-equity fund. At the time, the company said it expected to close in the second quarter of fiscal 2027, subject to approvals. It cleared those hurdles within the guided window and said the transaction is expected to be earnings-per-share accretive.
The market reaction framed the deal as a re-rating event for a small-cap API maker. On the day the acquisition was announced, GTBL's shares rose 4.01% to ₹383.65 in early BSE trade, after gaining 3.29% the previous session; the company's market value stood at ₹4,019.18 crore. By the close date on September 18, market capitalization had reached ₹5,562.70 crore, and the stock was trading near ₹427 - a gain of more than 56% over six months.
MBJ brings more than six decades of pharmaceutical R&D and manufacturing expertise, three GMP-compliant plants, and a track record of inspections by the US Food and Drug Administration and Japan's Pharmaceuticals and Medical Devices Agency. It reported revenue of ¥9.5 billion (about ₹570 crore) in fiscal 2026, with roughly 40% generated outside Japan. Its six largest customers have been with the company for more than two decades, and existing management will continue to run the Japanese operations.
The successful completion of this acquisition marks a defining milestone in GTBL's journey towards becoming a fermentation-based, globally integrated CDMO.
That assessment came from Dr. Sachin Patel, managing director of GTBL, as the company moved to combine its fermentation capabilities and manufacturing scale with MBJ's more than six decades of pharmaceutical R&D and its established relationships with global pharmaceutical companies.
Why a Private-Credit Fund, Not a Bank, Financed the Deal
The financing choice is the sharpest signal in the transaction. A manufacturer with a market capitalization of roughly ₹5,500 crore buying a foreign asset worth about a quarter of its own value would, a decade ago, have gone to its relationship banks for a syndicated loan or raised equity in the public markets. Instead, GTBL turned to Avendus Structured Credit Fund III, a private-credit vehicle that had just crossed ₹2,200 crore in investor commitments and was targeting a ₹4,000 crore corpus.
The mechanism is straightforward, and it explains why both sides said yes. Private-credit funds can underwrite bespoke, cross-border structures faster than banks bound by single-obligor limits, sector exposure caps, and conservative foreign-asset lending policies. For a borrower, the trade-off is cost for certainty and speed: the debt sits inside the Japanese acquisition vehicle, ring-fenced against the Indian parent, while GTBL's own balance sheet takes the equity tranche and a portion of the inter-corporate loan. For the lender, the structure offers secured exposure to a listed parent with a controlling stake in a cash-generative target - a risk profile that fits a high-yield credit mandate better than a plain corporate loan.
This is not an isolated experiment. India's private-credit market has grown from less than $0.7 billion in assets under management in 2010 to an estimated $17.8 billion in 2023. Deployment reached $9.0 billion across 79 deals in the first half of 2025 alone - already above the $7 billion to $10 billion recorded across all of 2024 and the $7.7 billion in 2023. At the same time, bank credit growth in India decelerated to 11% year-on-year in fiscal 2025, tightening the supply of conventional corporate lending just as mid-sized companies began looking overseas. The two trends meet in deals like this one: a funding gap on one side, dry powder on the other.
The second-order effect runs through the buyer pool, and it is larger than the headline suggests. If private credit can underwrite the debt leg of a $100 million-plus cross-border deal, the set of Indian companies capable of bidding for foreign assets widens beyond the large conglomerates that can access syndicated loans or foreign-currency bonds. That shifts M&A from a balance-sheet game to a structuring game - and hands the economics of the debt to funds that price risk, not relationships. For mid-cap management teams, the implication is concrete: a deal that a bank credit committee would have sliced into smaller tranches or declined can now be financed as a single package, with the lender taking covenant protection instead of collateral alone.
What GTBL Is Actually Buying
The strategic logic is cleaner than the financing headline. GTBL is a fermentation specialist - it makes Rifamycin-S, an intermediate for the tuberculosis drug Rifampicin, and Lovastatin, largely on a job-work basis. Its own revenue base is modest: ₹150.8 crore in fiscal 2025, rising to ₹165.8 crore in fiscal 2026. MBJ adds a proprietary P450 enzyme platform for enzyme-based bioconversion, plus capabilities in plasmid DNA, antibody-drug conjugate conjugation, and recombinant proteins. Its portfolio spans APIs and intermediates in oncology, immunosuppressants, peptides, and antibiotics.
Put differently, GTBL is buying technology and customer access, not just capacity. MBJ's revenue of ¥9.5 billion - roughly 3.8 times GTBL's fiscal 2025 revenue - has been broadly flat, but 40% of it comes from outside Japan, and its customer relationships run more than 20 years deep. GTBL's stated plan is to combine its lower-cost Indian manufacturing base with MBJ's technology and regulated-market credentials to move up the value chain into a globally integrated contract development and manufacturing organization.
The accretion math is the key claim, and it deserves scrutiny. MBJ's revenue base is several times the size of GTBL's own, so even a modest net margin on the Japanese business would add meaningfully to the parent's earnings per share - provided the purchase price does not embed overly optimistic synergy assumptions. The risk is execution: integrating a Japanese workforce, maintaining US FDA and PMDA compliance across three plants, and realizing cost synergies without disrupting long-standing customer supply lines. The company has flagged none of these as problems; the market will judge on the first two quarterly filings after close.
Cyclical Funding Gap or Structural Shift?
The deal sits at the intersection of a cyclical funding gap and a structural shift in how mid-market companies access capital. Getting this distinction right matters, because it determines whether the deal is a template or an anomaly.
The cyclical leg is real and measurable. Bank credit growth has slowed while equity markets have been selective, leaving a financing gap in the mid-market. Private-credit funds with dry powder - ASCF III was scaling toward ₹4,000 crore - have stepped into that gap. If bank lending re-accelerates and equity windows reopen, some of this flow could revert to traditional channels. That is the mean-reversion case, and it has history on its side: private credit often grows fastest when banks pull back, then stabilizes at a lower share when conventional lending returns.
The structural leg is stronger, and it rests on more than one transaction. Private credit in Asia-Pacific is projected to grow from $59 billion in 2024 to $92 billion by 2027, a compound annual growth rate of more than 20% over the past five years. The asset class has moved from a niche alternative to a mainstream funding source, with institutional allocations deepening. More importantly, the capability being built here - underwriting cross-border, ring-fenced acquisition debt for listed mid-caps - is a repeatable product, not a one-off rescue loan. Once a fund has priced and documented this structure once, the marginal cost of doing it again falls sharply. The same funds that financed this deal will market the template to the next mid-cap buyer; the arranger, Avendus Capital, will pitch the same structure to its wider client base.
The verdict: the funding gap is cyclical, but the channel is structural. Even if banks lend more freely, private credit has now demonstrated it can price and close a cross-border acquisition for a sub-₹6,000 crore listed company - a segment banks have historically underserved because the ticket is too small for a syndicate and too complex for a standard term loan. That does not revert.
The Counter-Thesis: Why This Could Be a One-Off
The strongest argument against reading too much into the deal is simple: GTBL's management already knew Avendus. The arranger had worked with the company before, and the fund's mandate - high-yield structured credit - fit a transaction that banks might have found too small or too complex. In that reading, this is a relationship-driven deal, not evidence of a broad market shift. The financing was tailored to one borrower's balance sheet and one target's jurisdiction; generalizing from it to an entire asset class is the classic error of mistaking a case study for a trend.
There is also the valuation and integration risk. MBJ's revenue has been flat for three years - ¥7.83 billion in fiscal 2023, ¥9.74 billion in fiscal 2024, ¥9.31 billion in fiscal 2025, and ¥9.5 billion in fiscal 2026 - and paying ¥21.5 billion for a company with stagnant top-line growth means GTBL is betting heavily on synergy realization and cross-selling into MBJ's global customer base. If the integration stumbles - regulatory inspection findings, customer attrition, or failure to transfer technology to India - the accretion turns into dilution, and the private-credit debt becomes a fixed cost the parent must service regardless of how the combined business performs.
The counter-thesis has force, but it does not overturn the structural read. Even if this specific deal underperforms, the financing template - private credit funding the debt leg of a cross-border acquisition, with the parent taking equity and a partial loan - is now documented and repeatable. The signal is about the channel, not the outcome of one transaction. A single failed deal would damage GTBL's stock; it would not erase the capability that Avendus and ASCF III have now demonstrated.
The falsifying test is concrete: if, over the next four quarters, fewer than three comparable mid-cap Indian cross-border acquisitions are financed with a meaningful private-credit component, the structural-shift thesis is wrong and this was a one-off. Track the financing disclosures of deals in the ₹500 crore to ₹2,000 crore range; a reversion to bank syndicates and equity raises would confirm the cyclical view.
Who Benefits, Who Is Exposed, and What to Watch
The immediate beneficiaries are clear. Private-credit funds with India mandates - the sector now includes domestic players such as Edelweiss Alternatives, 360 One, and Kotak Alternate Assets, alongside global names such as Ares, Oaktree, and KKR - gain a reference transaction for outbound acquisition financing. For mid-cap Indian manufacturers in fermentation, CDMO, and specialty chemicals, the deal lowers the perceived barrier to cross-border M&A: debt capacity no longer depends solely on a bank relationship.
The exposed are the traditional lenders. If acquisition debt migrates to funds that price risk and move faster, banks lose the fee income and the relationship leverage that comes with financing a client's growth. They can respond by loosening foreign-asset lending policies or by partnering with private-credit funds on club deals - but the pricing power has shifted. The banks that adapt will keep the deposits and the treasury business; the ones that do not will find their best corporate clients financing growth elsewhere.
Looking ahead, the time horizons point in different directions. In the short term, the trade is sentiment-driven: GTBL's shares have already rerated, and any delay in integration or a weak first quarter from MBJ could trigger a pullback. In the medium term, the EPS accretion and the revenue multiple MBJ adds will determine whether the rerating holds. In the long term, the question is whether this financing model becomes a repeatable channel for Indian outbound M&A - and that depends less on GTBL's outcome than on whether other mid-caps follow.
Base case: GTBL integrates MBJ without regulatory findings, realizes modest cost synergies, and the deal proves EPS accretive as promised - validating the private-credit template for similar-sized buyers. Upside case: MBJ's P450 platform and ADC capabilities open higher-margin CDMO contracts, and two or more comparable mid-cap deals follow within a year, confirming the structural shift. Downside case: integration stumbles, revenue synergies fail to materialize, and the market reverts to viewing this as a one-off relationship deal - with private credit returning to domestic working-capital and capex lending.
The watchlist is specific: GTBL's next two quarterly filings for any mention of integration costs or MBJ contribution; any regulatory inspection outcomes at MBJ's three plants; and the financing disclosures of the next wave of mid-cap Indian cross-border deals.
Gujarat Themis did not just buy a Japanese drugmaker - it bought a financing model, and the debt that paid for it may prove more valuable than the factories.
Explore more exclusive insights at nextfin.ai.
